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How can behavioural science help us
design better trials?
Katie Gillies1* , Jamie Brehaut2,3, Taylor Coffey1, Eilidh M. Duncan1, Jill J. Francis2,4, Spencer P. Hey5,6,
Justin Presseau2,3, Charles Weijer7 and Marion K. Campbell1
Background
Clinical trials remain the cornerstone of evidence-based
health care. As of July 1, 2021, there were 382,313 clin-
ical trials registered on ClinicalTrials.gov, an average of
33,400 new registrations over each of the past 3 years,
and 19,782 new registrations for this year (2021) alone
[1]. Even assuming modest sample sizes of 125 partici-
pants for each of those new 19,782 trials in that one
registry, these trials already require more than 2.4 mil-
lion participants this year, approximately 13,737 every
day, and hundreds of potential participants being
approached or being followed up right now.
Despite the incredible volume of research activity and
collective trial experience, trials still routinely take lon-
ger (and cost more) than originally proposed, often due
to challenges with recruitment (including participants in
a trial) and/or retention (keeping participants in a trial)
[2]. For example, only 56% of UK National Institute for
Health Research Health Technology Assessment funded
trials recruited the number of people they needed, and
some suffered loss to follow-up of up to 77% [2]. Along-
side challenges of recruitment and retention, many other
trial process-related deficiencies produce trial results
that are at best unreliable and at worst unusable leading
to research waste [3].
Amongst the existing evidence on how to improve the
design and conduct of trials, little attention has been given
to the integral and multifactorial role of human behaviour
to trial success. Indeed, all of these trials depend on be-
haviours: they rely on people (patients, clinicians, trial
staff) performing actions (such as receiving or delivering a
trial intervention, attending a clinic, returning a
questionnaire, or approaching eligible participants) that
they would not do otherwise. Clearly defining and specify-
ing behaviours is a key first step in clarifying behaviours in
terms of who needs to do what differently to/for whom
and when. The AACTT behaviour specification frame-
work was developed for implementation research and pro-
poses five domains (action, actor, context, target, time) to
describe and detail relevant behaviours [4]. The AACTT
framework can be used to specify the behaviours of indi-
viduals and to describe team and organisational behaviour.
Even considering a simple process such as developing
AACTT specifications for key trial activities (e.g. returning
a questionnaire) could provide considerable additional
insight. There are many influences on participants, trial
staff, and clinicians’ behaviours within clinical trials. These
trial-related behaviours are widespread, often contextually
dependent and amenable to change. Indeed, failure to rec-
ognise the behavioural influences (and change them where
appropriate) could contribute to the failure of the trial.
Moreover, insofar as behaviours are at the heart of clinical
trial delivery, then behavioural science—the study of be-
haviour and behaviour change—can provide critical, rep-
licable, and generalisable insights for the clinical trials
community.
The potential value of behavioural science to
inform trial design, delivery, and reporting
Behavioural science is cross-disciplinary and has been
considered as an umbrella term that includes contribu-
tions from various disciplines (including psychology,
economics, sociology, political science, and anthropol-
ogy). The field concerns how and why people behave as
they do. Behavioural science as applied to health seeks
to use the theories, methods, and knowledge from these
disciplines to design more effective health care interven-
tions. Within this article, we have focussed primarily on
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contributions from psychology but recognise that many
of the other disciplines may have important contribu-
tions for clinical trials. The application of behavioural
science to complex problems in health care has clearly
been effective in changing both patient (e.g., smoking
cessation) and health care professional behaviour (e.g.,
following recommendations for acute stroke care) as
well as improving patient outcomes on both the short
and long terms [5, 6]. For decades, implementation sci-
ence has informed how to improve the uptake of trial re-
sults into practice, but lessons from the wider field of
behavioural science have only recently been applied to
problems of trial design and delivery.
Clinical trials are complex and made up of multiple
processes at various stages of the trial lifecycle. These in-
clude, but are not limited to, question conception, trial
design, grant and protocol writing, planning trial deliv-
ery, recruitment, intervention delivery, data collection,
retention, analysis, dissemination of findings, and close-
down. Understanding the influences on trial processes as
multiple behaviours (performed by multiple actors),
across the trial life cycle, has the potential for developing
more effective evidence-based strategies for improve-
ment. For example, recruitment can be further broken
down to designing recruitment marketing materials (per-
formed by investigator teams), approaching all eligible
participants (performed by trial recruiters), signing of
the consent form (performed by recruiters and partici-
pants), etc. Once a trial process is broken down in this
way, it becomes more amenable to study and improve-
ment with the tools of behavioural science. In what fol-
lows, we will present detailed examples of how
behavioural science has been applied to trial processes in
just this way.
When is a trial needed?
It can be difficult to determine when the evidence is
strong enough to support the widespread implementa-
tion of an intervention or when further RCTs may be re-
quired. A study by Cuthbertson and colleagues sought
to identify why the ICU community had not widely
adopted the use of selective decontamination (SDD) of
the digestive tract in ICU patients given the substantial
evidence supporting the effectiveness of SDD from 12
meta-analyses of 36 RCTs [7]. Using a Delphi survey
based on the Theoretical Domains Framework (TDF),
the team were able to assess the factors affecting the
clinical behaviour and the appetite for a further RCT [7].
In brief, the TDF is a comprehensive framework that
proposes 14 theoretical domains that may influence
behaviour (e.g. knowledge, behavioural regulation, emo-
tion) [8]. Priority domains can be determined with re-
gard to facilitators or barriers to performing the
behaviour, which are then targeted when developing
behavioural interventions [9]. The Delphi study con-
cluded that the behaviours (in this case actively deliver-
ing SDD to ICU patients) would not be more widely
implemented without further supportive evidence given
the concern regarding the lack of appropriate/relevant
outcomes in the existing trial contexts. This work dir-
ectly informed the successful funding of an international
trial of SDD in ICU patients with hospital mortality (pri-
mary) and antibiotic usage/resistance (secondary) as out-
come measures. This approach of analysing the profile
of behavioural responses to determine whether further
(or indeed preliminary) trials are needed could be
adapted for many clinical questions as one of the first
steps in designing an RCT.
Is a trial feasible?
There are many ways that assessments of trial feasibility
can be conducted. One of the benefits of assessing trial
feasibility using a behavioural science approach is that it
offers detailed identification of barriers and potential facil-
itators to performing key behaviours, which, in turn, drive
the development of highly tailored, specific solutions with
real potential to overcome feasibility challenges. To in-
form a future large-scale evaluation of a prehospital
trauma intervention, ongoing work by Gillies et al. is de-
veloping a detailed behaviour specification and ‘diagnosis’
to identify the key challenges and opportunities for im-
proving the feasibility and ultimate success of the future
trial [10]. Specifically, interviewing health care profes-
sionals who are currently (or potentially would be) deliver-
ing the intervention will allow an understanding of
behavioural challenges in intervention delivery and will
provide evidence to help future strategies succeed for the
future randomisation of participants.
Understanding the broad challenges for potential trial
participants is also an important barrier to overcome
when recruiting to a trial. Some studies have used surveys
informed by behavioural theory, such as the health belief
model (a model that assumes people’s subjective health
considerations determine health-related behaviour), to in-
vestigate why patients choose to participate in trials [11,
12]. Brehaut and colleagues have taken this a step further
by developing a theory-guided TDF survey to identify the
challenges and opportunities to trial participation amongst
potential participants, rather than amongst those who
have participated [13]. The use of tailored surveys (which
could be informed by the Brehaut approach) can be ap-
plied pretrial to determine what the main barriers to trial
recruitment are likely to be and to facilitate recruitment
strategies to address these barriers.
Do trial teams involve patients and public partners?
There are many motivators for involving patients and/or
the public as research partners, not least of all to ensure
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the research is relevant for those it seeks to serve. The
involvement of the patient and public partners in trials
is now commonplace, but the extent and depth of that
involvement vary significantly. A recent study by Goulao
et al. surveyed trial teams to investigate the behavioural
determinants of involving patient partners in numerical
aspects of trials using a TDF-based survey [14]. The sur-
vey highlighted several domains that act as barriers
(knowledge; skills and beliefs about capabilities; re-
sources; reinforcement) which could be targeted with
behaviourally specified interventions to improve current
practice. This approach could be extended to the in-
volvement of other stakeholders in the trial design and
delivery process.
What are the challenges to trial recruitment?
Recruitment to clinical trials has been identified as the
top methodological priority by UK Clinical Trials Units
directors, evidencing its importance to many in the com-
munity [15]. Understanding the main challenges relating
specifically to trial recruitment has been the focus of
much research, but still very few high-quality, generalis-
able solutions exist [16]. A number of studies have ap-
plied behavioural science to understand the problems of
trial recruitment. This has included conducting behav-
ioural theory-informed qualitative interviews to under-
stand the potential challenges to recruitment to early
phase trials from the perspectives of clinicians and pa-
tients [17–20]. Findings from these studies were then
used to refine the design and conduct of future trials. In
addition to early phase trials, an exploratory TDF-based
approach is currently being used to understand the chal-
lenges faced by health care professionals when recruiting
pregnant women into clinical trials. The findings of the
interviews will be used to develop, and subsequently test,
a behaviour change intervention targeting professionals
to improve the recruitment of pregnant women [21]. A
similar approach has been used to develop an implemen-
tation intervention to address low recruitment to cancer
clinical trials amongst rural and minority community ur-
ology practices [22]. This implementation intervention,
termed ‘learn/inform/recruit’ was deemed appealing and
acceptable by stakeholders [22]. The theory of planned
behaviour (which proposes a model based on three vari-
ables: attitudes, subjective norms, and perceived behav-
ioural control, which work together to predict the
intention to perform a behaviour) has also been used to
explore trial recruitment [23, 24]. TPB was used as a
guiding framework to assess an intervention aimed at
supporting patients in making fully informed decisions
about lung cancer trials, highlighting that the application
of this approach can be used with a range of theoretical
approaches [23]. Using theoretical frameworks in this
way is helpful for the individual trials as it enables more
direct identification of possible strategies/techniques tai-
lored to address the construct/factors more readily. A
further advantage is this approach also allows the oppor-
tunity to combine data across studies and consider the
meta-level findings of relevance across (possibly similar
phased) trials.
Whilst many of the examples to date have been based
on the TDF, a range of other behavioural theories and
frameworks have been applied to problems of trial recruit-
ment and retention. A recent mapping review identified
31 studies that used a range of theories/frameworks in-
cluding the TDF, the theory of planned behaviour, social
cognitive theory (describes the influence of the actions of
others, experiences, and environmental contexts on an in-
dividual’s health behaviour), and others [Coffey et al.
manuscript under review [25, 26]]. Establishing whether
there are ‘best fit’ theories and frameworks for different
trial problems is an important consideration for future
work in this area.
How is the trial intervention delivered?
Process evaluations have long been embedded in rando-
mised evaluations of clinical interventions to understand
various aspects of delivery [27]. Many of these have in-
cluded behavioural theories that have underpinned the
behaviour change interventions being evaluated or in-
deed used theories (from a wide range of fields) to
understand the mechanisms of change or barriers to im-
plementation. However, less well addressed in this litera-
ture is the application of behavioural science to unpack
the behaviours and behaviour change required for the
delivery of clinical interventions within trials. Two re-
cent studies have aimed to do just that. The first was
with health care professionals delivering a trial of indivi-
dualised temperature-reduced haemodialysis to explore
the behaviours involved in adjusting the temperature on
a dialysis machine [28]. The second was using a theory-
based approach in data analysis gathered from both
health care professionals and patients to explore trial ex-
perience and beliefs and experiences of the intervention,
which in this case is catheter wash out policies [29].
What are the challenges to trial retention?
Similar to work on recruitment, a number of studies are
now emerging that have conducted qualitative interviews
informed by behavioural frameworks to understand trial
retention behaviours such as postal questionnaire return
and follow-up clinic attendance [30, 31]. Findings from
the interview studies were then used to develop
participant-centred, theory-informed interventions to
promote trial retention that have been codesigned with
stakeholders and will be tested in randomised evalua-
tions [32].
Gillies et al. Trials          (2021) 22:882 Page 3 of 7
The Cochrane reviews on interventions to improve recruit-
ment to and retention in clinical trials have found very little
evidence of effect [16, 33]. The reviews largely include inter-
ventions that were not designed as behaviour change inter-
ventions (BCIs) with only a minority (< 5%) conceptualised
as BCIs, yet the implicit aim of the majority is to change par-
ticipants’ recruitment or retention behaviour. For example,
intervention categories in both reviews include incentives
and rewards (which target the theoretical behavioural do-
main of reinforcement), reminders and prompts (target the-
oretical domain of memory, attention and decision-making,
environment context, and resources), and improvements to
information (target theoretical domain, knowledge). Yet, the
design and delivery of these interventions do not include the
explicit inclusion of behaviour change input, nor are these
interventions informed by the bodies of knowledge in the be-
havioural sciences. Deconstructing interventions into their
behaviour change techniques (BCT, defined as the smallest
‘active ingredient’ of an intervention that can be used alone
or in combination) has the potential to identify possible ‘ac-
tive ingredients’ which could be enhanced in future replica-
tions of evaluations or implementation [34]. Duncan et al.
demonstrated the potential value of this approach with pre-
liminary work identifying BCTs within interventions shown
to improve retention [35]. The findings identified that BCTs
were used amongst the interventions but not labelled as such
(notably incentives and prompts—both behavioural strat-
egies) and that several implicit BCTs were applied in both
intervention and control strategies. The need to explicitly in-
corporate BCTs during the design of interventions to target
recruitment and retention behaviours (and others relevant
for trial conduct) is key. A small number of studies have de-
veloped behaviour change interventions for trial retention by
incorporating BCTs into covering letters of questionnaires,
newsletters, and also use of trial stickers on envelopes (to act
as prompts) [36]. Preliminary evaluations of these behaviour-
ally focussed trial process interventions are showing promise,
but replication and further research to include patient input
and assessment are required to maximise their potential [33,
36]. Creating a shift in the conceptualisation of recruitment
and retention interventions to be considered (during design
and delivery) as behaviour change interventions may provide
more potential for more focused assessment of effectiveness
and may enhance replicability.
It is important to highlight that the examples provided
here are not an exhaustive list but are exemplars from key
trial life cycle stages that serve to show where existing em-
pirical studies have demonstrated the potential for a
behavioural approach to address trial process problems
(see Fig. 1). In particular, the challenges that many trials
have faced during the COVID-19 pandemic (such as the
move to remote delivery of recruitment, interventions,
and follow-up) also provide a wealth of opportunities to
apply behavioural approaches to generate evidence-
informed solutions from the perspective of trial teams,
regulators, and trial participants. A varied range of other
trial process problems could also benefit from this ap-
proach including (but not limited to) choosing outcomes,
participants’ experience, and sharing of trial results with
trial participants. In addition, several behavioural ap-
proaches such as multiphase optimisation strategies
(MOST), intervention mapping, and ‘nudging’ (a recent
focus in the behavioural economics literature) could also
warrant investigation in the future [37–39].
Core considerations for applying behavioural
approaches to trials
It is of greater importance than ever to ensure that any
strategies or approaches used in trials are sensitive to
the different needs of diverse trial populations. For ex-
ample, the majority of interventions targeting trial re-
cruitment and retention to date have been developed by
and tested in largely White populations [16, 33]. A re-
cent mapping review of the published studies that used
behavioural strategies to understand or develop solutions
to problems of trial recruitment and/or retention identi-
fied that 35% of studies (n = 11) were set within under-
served populations (Coffey et al., manuscript submitted
[25]). This may suggest the potential for behavioural ap-
proaches to begin to address some aspects of inclusion
of underserved communities in trials, ensuring that fu-
ture research considers equitable participation for all
[40]. However, the systemic structural and institutional
challenges of ensuring opportunities and access to re-
search are available for all and will also require work
that may extend beyond a behavioural framework.
Similarly, much of the work in this space is being con-
ducted in developed countries, but there are now projects
being developed which also plan to use a behavioural sci-
ence approach in trials in low- and middle-income coun-
tries. One such study is focussing on the behaviours of
postal questionnaire return and follow-up clinic attend-
ance after surgery in a number of LMICs (e.g. India, South
Africa, Philippines). This project will apply the capabilities,
opportunity, and motivation behaviour system (COM-B)
to provide a behavioural diagnosis and identify interven-
tion functions that then help to assess the relevance of
existing interventions to modify target behaviours and as
such ‘treat’ the problems [41].
It is also worth considering not just how behavioural
science can maximise learning opportunities at key
stages of trial design and delivery, but also its potential
value across different phases of trials and trials of vari-
ous intervention types, e.g. clinical trials of investiga-
tional medicinal products (CTIMPs) and non-CTIMPS.
For example, we know that the motivations of partici-
pants to participate first in human studies are largely dif-
ferent to the motivations of those who participate in
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later stage pragmatic effectiveness trials and are often
linked to risk [42, 43]. It may also be that these ap-
proaches could be more or less acceptable for trials in
particular clinical contexts (e.g. emergency care) or pop-
ulations (e.g. children or adults who lack capacity). Con-
siderations of risk, whether in relation to the stage of
evaluation or the interventions under investigation, also
raise another important consideration.
There will of course be some core challenges for trial
teams in applying a behavioural approach to trials. Some
of these may relate to trial teams lacking confidence or
knowledge in how to apply particular theories or frame-
works. The best option would likely be to include behav-
ioural scientists as part of the trial team but failing that,
tools that make this approach accessible and implemen-
table will be key. A good starting point exists amongst
key papers for health behaviour change, in particular,
some worked examples of how to apply the AACTT
framework [4], a step-by-step guide to using the TDF
[9], a guide for constructing questionnaire informed by
the TPB [44], and a core textbook on the behaviour
change wheel which covers COM-B interventions and
includes lots of practical examples of application albeit
in a different context [45].
The ethics of behaviour change interventions requires
further exploration. Will certain behavioural approaches,
and therefore particular behaviour changes interven-
tions, be more ethical in some trials over others? For in-
stance, the use of ‘nudges’ in informed consent has been
criticised on ethical grounds [46]. But should behaviour
change interventions be conceptualised as nudges, and
outside of the consent process, what is their impact on
the autonomy of trial participants? Where are the limits
to when behaviour change interventions become more
or less acceptable, practically and philosophically, in the
context of trial-related behaviours?
One ethical advantage to framing trial processes as
complex behaviours is that, by unpacking the various be-
haviours, actors, and influences involved in any process,
it becomes clear how trial success is a social
phenomenon—that is, trial funders, investigators, re-
cruiters, and patients all need to act in particular ways at
particular times in order for the trial to achieve its scien-
tific and social aims. For example, the model of the re-
cruitment process that we described above includes
behaviours, and therefore potential interventions, that
would target investigators, recruiters, or patients. By
contrast, the existing literature on nudges in trials has
tended to focus almost exclusively on interventions that
would target patient behaviour—who are often going to
be the most vulnerable stakeholders. Whilst focusing on
patient behaviour is certainly important, by widening the
behavioural lens, so to speak, the model we advocate
opens up possibilities to study and improve trial behav-
ioural with a more holistic, and potentially more equit-
able, approach.
Lastly, it will be important to ensure that behavioural in-
terventions or approaches seeking to address trial prob-
lems are evaluated using robust approaches such as
Studies Within A Trial (SWATs), or other appropriate
Fig. 1 Trial lifecycle highlighting example trial processes and potential application of the behavioural science approach
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study designs, to determine the effectiveness and mecha-
nisms of effect and to identify potential behavioural con-
founders in trial conduct [47]. Ensuring interventions and
processes for evaluation are detailed and pre-specified in
publicly available protocols will help to encourage replica-
tion by other teams across a range of trials.
The added value of behavioural approaches to
trial design and conduct
There is considerable potential for the behavioural ap-
proach to trials in that it offers significant flexibility. For
example, this approach can be applied before a trial is
started, can be implemented with multiple methods, and
is theory-informed. A further added value component of
developing the methodology around behavioural opti-
misation and operational strategies for clinical trials will
be the greater potential for sharing resources and learn-
ing across data sets. The potential for aggregation of
diagnostic behavioural data across trial types, collected
using the same tools, to explore the over-arching chal-
lenges and opportunities facing clinical trials has huge
potential. Further enhancing the potential for learning
across trials and the application of transferable solutions
should be a focus going forward. Current research to de-
termine the best practices for sharing qualitative data in
clinical trials will demonstrably help move this agenda
forwards [48].
Conclusions
Trialists are implicitly using behavioural approaches
already. Fully engaging with the science may help to make
more explicit decisions for what behavioural strategies to
include and why at each stage of a trial. This explicit oper-
ationalisation of a behavioural approach would enable the
greater potential for generalisability and shared accumula-
tion of evidence to ensure that the funding, and the time
and effort trial teams and trial participants contribute are
maximised. Ultimately, accelerating the availability of new
therapies to better the health of the population. Adopting
a behavioural approach to address problems of trial design
and conduct has been shown to be an effective, reprodu-
cible, transparent, and generalisable approach. As this is
an emerging field, however, thoughtful consideration and
empirical work to establish the most suitable approaches
to a range of trial problems and contexts, whilst develop-
ing implementable methodology supported by appropriate
resources, is a key next step.
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